Informações:
Falhas:
ID
14354
Descrição
Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01226303
Link
https://clinicaltrials.gov/show/NCT01226303
Palavras-chave
Versões (1)
- 12/04/2016 12/04/2016 -
Transferido a
12 de abril de 2016
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Acute Promyelocytic Leukemia NCT01226303
Eligibility Acute Promyelocytic Leukemia NCT01226303
- StudyEvent: Eligibility
Similar models
Eligibility Acute Promyelocytic Leukemia NCT01226303
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Acute Promyelocytic Leukemia
Item
patients with a clinical diagnosis of initial apl and subsequently confirmed to have pml-rarα, npm1-rarα or numa-rarα fusion. whilst this study is only for atra-sensitive apl, apl is a hematological emergency and atra should be commenced as soon as the diagnosis is suspected. study entry should not wait until the diagnosis of apl has been confirmed molecularly or cytogenetically
boolean
C0023487 (UMLS CUI [1])
Age
Item
less than 21 years of age at initial diagnosis (for aieop, see appendix a)
boolean
C0001779 (UMLS CUI [1])
Anthracyclines
Item
considered suitable for anthracycline-based chemotherapy
boolean
C0282564 (UMLS CUI [1])
Informed Consent
Item
Informed Consent
boolean
C0021430 (UMLS CUI [1])
Patient not pregnant
Item
Negative serum test to rule out pregnancy within 2 weeks prior to registration in females of childbearing potential (non childbearing potential defined as premenarchal, greater than one year post-menopausal, or surgically sterilized)
boolean
C0232973 (UMLS CUI [1])
RARA/ZBTB16 Fusion Protein
Item
patients with a clinical diagnosis of apl but subsequently found to have plzf-rarα
boolean
C3537406 (UMLS CUI [1])
Retinoic Acid Receptor
Item
fusion or lacking pml-rarα, npm-rarα or numa-rarα rearrangement should be withdrawn from the study and treated on an alternative protocol.
boolean
C0140278 (UMLS CUI [1])
Relapse
Item
refractory/relapsed apl (the guidelines in this protocol for that subgroup are intended for patients treated from initial diagnosis according to this protocol)
boolean
C0035020 (UMLS CUI [1])
Malignant Neoplasms
Item
concurrent active malignancy
boolean
C0006826 (UMLS CUI [1])
Pregnant or lactating
Item
Pregnant or lactating
boolean
C0549206 (UMLS CUI [1])
C2828358 (UMLS CUI [2])
C2828358 (UMLS CUI [2])
Chemotherapy Regimen
Item
physician and patient/guardian think that intensive chemotherapy is not an appropriate treatment option
boolean
C0392920 (UMLS CUI [1])
Tretinoin
Item
patients who have received alternative chemotherapy for 7 days or longer without atra for any reason (either apl not initially suspected or atra not available).
boolean
C0040845 (UMLS CUI [1])